CG Oncology: Priced To Perfection On Future Pipeline Success
CG Oncology Inc CGON
$71.19
▼ -2.52%
($-1.84)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$72.94
Prev Close
$73.03
Day Range
$69.60 – $72.94
52W Range
$23.65 – $77.00
Market Cap
$6.28B
Beta
0.17
EPS (TTM)
$-2.34
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-01-25 |
| Shares Out. | 88,200,000 |
| Website | cgoncology.com/ ↗ |
| Phone | 13025310855 |
| Employees | 142 |
| Revenue | $1.1M |
| Gross Profit | -$1.9M |
| Net Income | -$60.2M |
| Free Cash Flow | -$160.4M |
| Total Assets | $1.14B |
| Total Liabilities | $43.5M |
| Equity | $1.09B |
About CG Oncology Inc
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
CG Oncology Inc is a publicly traded company under the ticker symbol CGON on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-07-01)